XNOM News Xenomics' Breakthrough Transrenal-DNA Technology Platform to be Presented at Bio InvestorForum in San Francisco; Revolutionary DNA Testing Technology Could Provide Completely Noninvasive Detection Alternative for Major Diseases
NEW YORK--(BUSINESS WIRE)--Oct. 11, 2005--Xenomics, Inc. (OTCBB:XNOM) (FWB:XE7), a developer of next-generation medical DNA technologies, will present its breakthrough proprietary Transrenal-DNA technology platform for the safe, accurate and noninvasive detection and monitoring of a range of diseases and genetic conditions, at the Bio InvestorForum 2005, 10 a.m. October 20, at the Palace Hotel in San Francisco, CA.
CEO Dr. Randy White will provide a corporate overview and highlights of Xenomics' proprietary Transrenal-DNA (Tr-DNA) technology, a potentially revolutionary medical diagnostic technology, which has broad applications for monitoring and/or detection of diseases and conditions including HIV, Tuberculosis (TB), Down syndrome and other fetal genetic abnormalities. His presentation will be webcast simultaneously.
"Xenomics has continued to achieve its research and development milestones as we work toward commercializing our Transrenal-DNA medical diagnostic technology," said Dr. White. "Our primary mission is to transform our proprietary Tr-DNA platform technology into a new category of medical urine tests for an expanding range of diagnostic and health-monitoring applications, such as a simple but advanced urine test for pregnant women that effectively, accurately and easily screens for Down syndrome and other fetal genetic abnormalities. Other applications of our Tr-DNA technology in our product development pipeline include urine sample tests for cancer and infectious diseases such as malaria and HIV."
Among the participants and attendees expected at Bio InvestorForum 2005 are public and private equity investors, research analysts, investment bankers and senior-level industry executives focused on investment trends and business development opportunities in life sciences, according to organizers.
Xenomics' diagnostic technology is based on the noninvasive sampling of DNA material that passes transrenally, or through the kidneys, and is excreted in urine. Xenomics scientists were the first to detect Tr-DNA and to determine that it can be used to detect and monitor a broad range of diseases and genetic conditions.
The Company is using the technology to develop safe and accurate medical testing products to provide a cost-effective, medically advantageous alternative to diagnostic methods now in use. Most existing medical DNA diagnostic tests use blood or tissue samples from invasive tissue biopsies, which are generally more difficult, riskier and more expensive to obtain.
Bio InvestorForum 2005, "Showcasing the Leading Growth Companies in Life Sciences," is a national investor forum to explore investment trends and opportunities in life sciences, with a focus on public and venture-stage growth companies as well as those poised to join the growth "watch list" in 2006. This Forum will deliver a rich program featuring corporate presentations and panel debates on the sweet spots and growth challenges facing the industry, with more than 190 public and venture-stage company presentations included. For more information, please visit: http://becif.bio.org/opencms/bif/2005/index.jsp.
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a corresponding allowed European patent for the Company's prenatal testing applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Istituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://xenomics.com. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html. Xenomics is also listed on the Frankfurt Stock Exchange under the symbol XE7.
Forward-Looking Statements
Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the periodic reports of Xenomics, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
